|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Liver Fibrosis | |||||
| Cirrhosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Fibrosis | |||||
| Hepatitis | |||||
| Hepatitis C | |||||
| Liver Cirrhosis | |||||
| 3 | More general conditions related to this trial | ||||
| Digestive System Diseases | |||||
| Flaviviridae Infections | |||||
| Hepatitis, Viral, Human | |||||
| Liver Diseases | |||||
| Pathologic Processes | |||||
| RNA Virus Infections | |||||
| Virus Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| interferon gamma-1b | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Interferon Alfa-2b | |||||
| Interferon Type II | |||||
| Interferon-gamma, Recombinant | |||||
| Interferons | |||||
| 6 | More general drug interventions related to this trial | ||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Anti-Infective Agents | |||||
| Antineoplastic Agents | |||||
| Antiviral Agents | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| InterMune | |||||